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Abstract. Breast cancer metastasis is one of the major reasons 
for the high morbidity and mortality of breast cancer patients. In 
spite of surgical interventions, chemotherapy, radiation therapy 
and targeted therapy, some patients are considering alternative 
therapies with herbal/natural products. In the present study, we 
evaluated a well-characterized extract from the medicinal mush-
room Ganoderma lucidum (GLE) for its affects on tumor growth 
and breast-to-lung cancer metastasis. MDA-MB-231 human 
breast cancer cells were implanted into the mammary fat pads of 
nude mice. GLE (100 mg/kg/every other day) was administered 
to the mice by an oral gavage for 4 weeks, and tumor size was 
measured using microcalipers. Lung metastases were evaluated 
by hematoxylin and eosin (H&E) staining. Gene expression in 
MDA-MB-231 cells was determined by DNA microarray anal-
ysis and confirmed by quantitative PCR. Identified genes were 
silenced by siRNA, and cell migration was determined in Boyden 
chambers and by wound-healing assay. Although an oral admin-
istration of GLE only slightly suppressed the growth of large 
tumors, the same treatment significantly inhibited the number of 
breast-to-lung cancer metastases. GLE also downregulated the 
expression of genes associated with invasive behavior (HRAS, 
VIL2, S100A4, MCAM, I2PP2A and FN1) in MDA-MB-231 
cells. Gene silencing of HRAS, VIL2, S100A4, I2PP2A and FN1 
by siRNA suppressed migration of MDA-MB-231 cells. Our 
study suggests that an oral administration of GLE can inhibit 
breast-to-lung cancer metastases through the downregulation 
of genes responsible for cell invasiveness. The anti-metastatic 
benefits of GLE warrant further clinical studies.
Introduction
Breast cancer is a leading cause of cancer death in women 
worldwide and the second leading cause of cancer death in the 
United States (1,2). The high mortality among cancer patients 
is associated with cancer metastasis, which contributes to more 
than 90% of cancer-related fatalities (3). Although chemotherapy, 
radiation therapy and targeted therapy can directly kill cancer 
cells, some cancer cells are resistant to these treatments and can 
further proliferate and metastasize. Therefore, identifying new 
drugs/compounds with an anti-invasive potential would help to 
control the metastatic properties of cancer cells. Interestingly, 
some natural/dietary compounds show the potential to suppress 
proliferation and invasiveness of cancer cells (4).
One of the dietary compounds not widely consumed in the 
United States is the mushroom. However, two recent epidemio-
logical studies from Asia suggest that mushrooms can actually 
protect against breast cancer (5,6). Ganoderma lucidum is a 
mushroom recognized by traditional Chinese medicine (TCM) 
and commonly used in the forms of tea, powder and dietary 
supplements (7). The botanical characterization, descrip-
tion and therapeutic effects of G. lucidum are summarized 
in the American Herbal Pharmacopoeia (Reishi Mushroom; 
www.herbal-ahp.org). We have previously shown that 
G. lucidum extract (GLE) containing triterpenes and polysac-
charides, suppresses the invasive behavior of breast cancer 
cells (8,9). Experimental in vivo studies demonstrated the 
inhibition of liver and lung metastases of lung carcinoma cells 
by triterpenoid fraction of G. lucidum and isolated ganoderic 
acid Me (GA-Me) and T (GA-T), respectively (10-12). In addi-
tion, 2.5% of the antlered form of G. lucidum in the diet 
suppressed the number of lung metastases of lung cancer 
cells (13). Oral administration of a lucidenic acid-rich 
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G. lucidum extract inhibited lung and liver metastases of 
human hepatoma cells in a xenograft model (14).
In the present study, we evaluated the effect of GLE on the 
growth and breast-to-lung cancer metastasis in an orthotopic 
xenograft model without significantly influencing primary 
tumor growth. Our data suggest that an oral application of GLE 
inhibits lung metastases and can be used for the natural/alter-
native therapy of invasive breast cancers.
Materials and methods
Materials. Human breast cancer cells (MDA-MB-231) were 
obtained from ATCC (Manassas, VA). MDA-MB-231 cells 
were maintained in DMEM medium supplemented with peni-
cillin (50 U/ml), streptomycin (50 U/ml), and 10% fetal bovine 
serum (FBS). Media and supplements were from Invitrogen 
(Grand Island, NY). FBS was obtained from Hyclone 
(Logan, UT). GLE was supplied by Pharmanex (Provo, UT). 
GLE is a standardized Ganoderma lucidum extract containing 
6% triterpenes and 13.5% polysaccharides; the extraction 
procedure was previously described (15). GLE stock solution 
was prepared in water for animal experiments or in DMSO for 
cell culture experiments. siRNA reagents, scrambled siRNA 
and siRNA for HRAS, VIL2, S100A4, MCAM, I2PP2A, and 
FN1 were from Santa Cruz Biotechnology (Santa Cruz, CA).
Human breast tumor xenograft experiments. MDA-MB-231 
cells (1x106) in 0.2 ml DMEM were injected into the mammary 
fat pad of 6- to 7-week-old female nude mice (Harlan, 
Indianapolis, IN), as previously described (16). Three to 
four weeks after implantation with tumor cells, when tumors 
reached approximately 600 mm3, the animals were randomized 
into control and treatment groups (18 animals per group). The 
animals received intragastrical gavage every other day with 
water (control) or 100 mg GLE/kg of body weight (treatment) 
for an additional 28 days. The tumor size was measured using 
calipers, and the tumor volume was estimated by the formula: 
tumor volume (mm3) = W2 x L x 1/2, where L is the length 
and W is the width of the tumor. At the end of the experiment 
(day 28), the lungs were harvested and fixed in 10% neutral 
buffered formalin at 4˚C for 24 h. Tissue was then processed 
overnight and embedded in paraffin. Five‑micrometer sections 
were stained with hematoxylin and eosin (H&E), and the metas-
tases in whole sections of stained lungs from 6 animals in each 
of the control and GLE-treatment groups were evaluated under 
a light microscope by 3 independent observers. The protocol 
for animal experiments was approved by the Animal Research 
Committee at IU Health Methodist Hospital according to the 
NIH guidelines for the Care and Use of Laboratory Animals.
DNA microarrays. MDA-MB-231 cells were treated with GLE 
(0 and 1.0 mg/ml) for 24 h and total RNA was isolated with 
RNAeasy (Qiagen, Valencia, CA). This RNA was used for the 
evaluation of gene expression with Oligo GEArray Human 
Tumor Metastasis Microarray according to the manufacturer's 
protocol (SA Biosciences, Frederick, MD, USA).
Quantitative RT-PCR. The quantitative real‑time polymerase 
chain reaction (qRT‑PCR) was performed using the ABI Prism 
7900HT Fast Real‑Time PCR System (Applied Biosystems, 
Foster City, CA) according to the manufacturer's instructions. 
MDA-MB-231 cells were treated with GLE (0 and 1.0 mg/ml) for 
24 h and total RNA was isolated using RNAeasy (Qiagen). The 
RNA samples were reverse transcribed into cDNA (RT‑PCR) 
using random hexamer primers and the TaqMan reverse tran-
scription kit (Applied Biosystems). The cDNA (100 ng per 
sample) was subjected to qPCR analysis in quadruplicate using 
forward and reverse primers, the TaqMan Universal Master 
Mix, and a probe (10 µl per reaction) in fast optical 96-well 
plates. The data were analyzed using the ABI Prism 7900 rela-
tive quantification (∆∆Ct) study software (Applied Biosystems). 
We used primers for HRAS, VIL2, S100A4, MCAM, I2PP2A 
and FN1 genes with the β-actin gene as the internal control 
(Applied Biosystems). The gene expressions levels were 
normalized to β-actin and are presented as arbitrary fold 
changes compared between the control and GLE-treated cells.
siRNA experiments. MDA-MB-231 cells (2x105) were seeded 
into 6‑well plates and incubated at 37˚C in a 5% CO2 incu-
bator until 70‑80% confluent. The cells were transfected with 
control RNA (scrambled, scRNA) or siRNA according to the 
manufacturer's protocol (Santa Cruz Biotechnology). Gene 
silencing by siRNA in MDA-MB-231 cells was evaluated by 
western blot analysis.
Western blot analysis. MDA-MB-231 cells were treated with 
GLE (0 and 1.0 mg/ml) for 24 h. Whole cell extracts were isolated 
as described (15), membrane extracts were isolated by using 
a ProteoExtract® subcellular proteome extraction kit (Merck, 
Darmstadt, Germany) according to the manufacturer's protocol. 
Protein expression was detected by western blot analysis with the 
corresponding antibodies anti-HRAS, anti-ezrin, anti-S100A4, 
anti-MCAM, anti-SET, anti-fibronectin, and anti-β-actin, 
anti‑GAPDH, and anti‑α-integrin 3 as loading controls 
(Santa Cruz Biotechnology) as previously described (15). Reactive 
bands were visualized with a respective secondary antibody via 
an enhanced chemiluminescence (ECL) detection system.
Cell migration assay. The effect of gene silencing on cell migra-
tion of MDA-MB-231 cells was assessed in Boyden chambers 
as previously described (17). After fixing and staining, the 
number of migrating cells was counted from at least four 
random fields using a microscope at x20 magnification (17). 
Data points represent the average SD of individual filters within 
one representative experiment repeated at least twice.
Wound healing assay. MDA-MB-231 cells were untransfected 
(control) or transfected with scRNA or siRNAs. After 24 h 
the cells were scratched using a 200-µl pipette tip and further 
incubated for an additional 24 h. The extent of wound healing 
was observed microscopically and recorded.
Statistical analysis. Data are represented as mean ± SD and 
were analyzed using SigmaPlot 11.2 (Systat Software Inc, 
San Jose, CA, USA).
Results and Discussion
Although previous studies demonstrated the suppression of 
tumor growth and the inhibition of metastases by purified 
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Ganoderma lucidum compounds or extracts in experimental 
animals, these studies usually started the treatment with small 
tumors close to 100 mm3 in size (12,14). Since not all breast 
cancers are diagnosed in the early stages, we were interested 
to learn whether GLE inhibits the growth and metastases 
of larger tumors. Highly invasive human breast cancer cells 
MDA-MB-231 were injected into the mammary fat pads of mice, 
and an oral application of GLE (100 mg/kg/body weight every 
other day) was started when the tumors reached 600 mm3. GLE 
treatment for 4 weeks had modest inhibitory effects on tumor 
size and weight (Fig. 1). Since we have previously shown that 
GLE inhibits invasive behavior in MCF-7 and MDA-MB-231 
breast cancer cells in vitro (8,9), we further studied whether 
GLE inhibits breast-to-lung cancer metastases in vivo. Although 
we did not observe changes in the tumor volumes in the control 
and GLE-treatment groups in MDA-MB-231 cell-derived 
tumors (Fig. 1A), we found statistically non‑significant inhibi-
tion of tumor growth by GLE (Fig. 1B). This effect was caused 
by the necrosis since both control and GLE-treated tumors had 
necrotic central regions that were filled with fluid. However, our 
data show significant inhibition of breast‑to‑lung cancer metas-
tases from 33.9±15.2 in control to 10.2±5.4 in GLE-treated 
animals (P<0.001) (Fig. 1C and D).
In order to identify which pro-metastatic genes are 
affected in MDA-MB-231 cells by GLE, MDA-MB-231 cells 
were treated with vehicle or GLE (24 h, 1.0 mg/ml) and gene 
expression was analyzed by Oligo GEArray Human Tumor 
Metastasis Microarray as described in Materials and methods. 
GLE treatment downregulated the expression of HRAS, VIL2, 
S100A4, MCAM, I2PP2A and FN1 genes by more than 20%, 
which we further confirmed by qRT‑PCR (Fig. 2).
Figure 1. Effect of GLE on tumor growth and breast-to-lung cancer metastases. MDA-MB-231 breast cancer cells were implanted in the mammary fat pads 
of nude mice and treated with GLE as described in Materials and methods. (A) The size and (B) weight of tumors were measured after 28 days (n=16-18). 
(C) Representative H&E stained lungs from control and GLE‑treated groups; black arrows indicate metastasis. (D) Lung metastases were quantified as described 
in Materials and methods (P<0.001, n=6).
Figure 2. Effect of GLE on human tumor metastasis genes. MDA-MB-231 cells 
were treated with vehicle or GLE for 24 h and the gene expression was deter-
mined by Oligo GEArray Human Tumor Metastasis Microarray and confirmed 
by qRT‑PCR as described in Materials and methods. The data are averages 
from 2 (microarray) and 4 (qRT‑PCR) experiments. The fold change is relative 
to vehicle-treated cells.
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Figure 3. Effect of genetic silencing of GLE downregulated genes on cell migration. MDA-MB-231 cells were untransfected (control) or transfected with 
scrambled (sc‑siRNA) or specific gene siRNA and cell migration and proper gene silencing was evaluated as described in Materials and methods. (A) HRAS, 
(B) VIL2 (ezrin), (C) S100A4, (D) MCAM, (E) I2PP2A (SET), (F) FN1 (fibronectin). The data are mean ± SD (n=3), P≤0.05 by ANOVA. Western blots show 
representative experiment.
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To confirm that genes targeted by GLE are indeed respon-
sible for the invasiveness of MDA-MB-231 cells, we silenced 
these genes by siRNA to evaluate whether this genetic manipula-
tion suppressed the migration of MDA-MB-231 cells. Increased 
expression of the oncogene HRAS is associated with aggressive 
breast cancer, and an overexpression of HRAS induces cell 
migration and an invasive phenotype in breast epithelial cells 
(18). Not surprisingly, HRAS silencing suppressed the migration 
of MDA-MB-231 cells (Fig. 3A). In agreement with a previous 
study by Li et al (19) on the silencing of VIL2, coding ezrin 
(VIL2), a cytoplasmic peripheral membrane protein that plays 
a key role in cell motility, slightly suppressed the migration of 
MDA-MB-231 cells (Fig. 3B). The S100A4 protein is overex-
pressed in highly metastatic cancers and controls cell migration 
through different pathways (20). Gene silencing of S100A4 also 
suppressed the migration of MDA-MB-231 cells (Fig. 3C). At 
Figure 4. Pooled siRNA inhibits cell migration. MDA‑MB‑231 cells were untransfected (control) or transfected with scrambled (sc‑siRNA) or a pool of siRNAs, 
(pooled‑siRNA, containing HRAS‑siRNA, VIL2‑siRNA, S100A4‑siRNA, MCAM‑siRNA, I2PP2A‑siRNA, and FN1‑siRNA). Cell migration was evaluated by 
(A) the wound healing assay and (B) cell migration assay described in Materials and methods. The data are mean ± SD (n=3), p≤0.05 by ANOVA. (C) Representative 
western blots from MDA‑MB‑231 cells transfected with scrambled siRNA (SC) or pooled‑siRNA (PO), or treated with GLE (GLE) or control (C).
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the time of our manuscript preparation, Wang et al (21) demon-
strated that gene silencing of S100A4 inhibited cell migration 
and invasion as well as lung metastases of MDA-MB-231 cells 
in mice. Although the original studies suggested that MCAM 
(also known as CD146 membrane glycoprotein) is a tumor 
suppressor in breast carcinomas (22), CD146 expression was 
later associated with a poor prognosis in breast cancer patients 
and increased motility of breast cancer cells (23,24). However, 
gene silencing of MCAM did not affect the migration of 
MDA-MB-231 cells (Fig. 3D). The SET protein (gene I2PP2A) 
inhibits protein phosphatase 2A (PP2A), which regulates 
oncoproteins (e.g. c-Myc, Bcr-Abl) in various cancers (25,26). 
Therefore, the inhibition of I2PP2A is therapeutically important, 
and, as recently demonstrated, targeting SET suppresses lung 
tumors (27). As seen in Fig. 3E, gene silencing of I2PP2A also 
suppressed SET protein expression and the inhibited migration 
of MDA‑MB‑231 cells. The fibronectin 1 protein (gene FN1) 
controls cell adhesion and migration, and FN1 overexpression 
was detected in breast cancer metastases (28,29). Gene silencing 
of FN1 resulted in the downregulation of FN1 expression and 
inhibited the migration of MDA-MB-231 cells (Fig. 3F). Since 
cell migration is a complex process and is controlled by more 
than one protein, we evaluated whether the gene silencing of all 
genes whose expression was downregulated by GLE treatment 
inhibited cell migration to a larger extent than the silencing of 
these genes individually. MDA-MB-231 cells were transfected 
with a mixture of siRNAs for HRAS, VIL2, S100A4, MCAM, 
I2PP2A and FN1, and cell migration was evaluated. As seen in 
Fig. 4A, transfection of pooled siRNAs suppressed migration in 
the wound-healing assay as well as in the cell migration assay 
in Boyden chambers (Fig. 4B), suggesting that targeting a pool 
of pro-invasive genes is a better strategy than targeting only 
one gene. On the other hand, the expression of ezrin, S100A4, 
MCAM, SET and fibronectin was downregulated by pooled 
siRNA, whereas the expression of HRAS was not affected 
(Fig. 4C). In addition, pooled siRNA and GLE treatment 
demonstrated the strongest inhibition of fibronectin expression, 
suggesting that fibronectin is the major target for inhibiting cell 
invasiveness. Although our data with pooled siRNA generally 
confirms our previous results with the isolated siRNA (Fig. 3), 
it is possible that pooled siRNA could also inhibit some of the 
single siRNA since HRAS-siRNA downregulated expression of 
the HRAS protein, whereas pooled siRNA does not. In addition, 
GLE treatment suppressed expression of different pro-invasive 
proteins with different potency, further suggesting specific 
targeting at transcriptional or posttranslational levels. These 
questions will be addressed in our future studies.
In our present study, we found that GLE downregulates the 
expression of a set of genes (HRAS, VIL2, S100A4, MCAM, 
I2PP2A and FN1) that are different from the previously published 
genes that mediate breast-to-lung cancer metastasis (30). One 
of the reasons for this difference is that in our experiments we 
originally evaluated the effect of GLE on the expression of 
selected pro-metastatic genes by using Oligo GEArray, which 
does not cover all genes. Moreover, the breast-to-lung meta-
static genes identified by Minn et al (30) were overexpressed 
in the lung-metastatic derivative of MDA-MB-231 but not in 
the parental MDA-MB-231 cells used in our study. Therefore, 
a different set of genes should be targeted during the progres-
sion of metastatic breast cancer. In addition, our study was 
performed with only one cell line of highly metastatic triple 
negative breast cancer cells, MDA-MB-231 and different genes 
can be targeted in other metastatic breast cancers.
In conclusion, the chemically characterized dietary mush-
room extract GLE inhibits breast-to-lung cancer metastasis of 
highly invasive human breast cancer cells implanted in mouse 
mammary tissue. In addition, GLE suppresses the expression 
of genes involved in the invasive behavior of cancer cells. 
Further preclinical studies evaluating GLE activity in the 
prevention of breast cancer metastasis are warranted.
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